生物医药ETF（512290）涨超1.1%，短期调整释放风险或迎布局窗口

Group 1 - The article emphasizes the strategic significance of innovative drugs and suggests improving capital market support and intellectual property protection mechanisms [1] - A notable adjustment in the biopharmaceutical sector has occurred, with significant corrections observed this week, following a strong performance of the innovative drug sector since the beginning of the year [1] - The National Medical Products Administration (NMPA) has proposed a draft for public consultation to expedite the review and approval process for clinical trial applications of innovative drugs, aiming for completion within 30 working days [1] Group 2 - The adjustment of the medical insurance catalog is about to commence, with the inclusion of innovative drugs in the commercial health insurance catalog, suggesting a focus on selection principles and price negotiations in future policies [1] - The NMPA has deployed a series of innovative support policies to promote the development of high-end medical devices, including medical robots and advanced medical imaging equipment, indicating new growth opportunities in this sector [1] - The biopharmaceutical ETF tracks the CS Biomedicine Index, which reflects the overall performance of listed companies in the biopharmaceutical industry, showcasing significant industry concentration and growth characteristics [2]